February 26, 2026
Three days, three signals: What some of the recent pharma deals and earnings reveal about 2026 strategy
A wave of oncology M&A, targeted mid-cap acquisitions, and cautious earnings guidance suggests pharma is entering a new capital discipline cycle. Here’s what investors should watch.